A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
BACKGROUND
Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation. However new reports are also emerging that suggest greater immunosuppression and risk for fungal disease.


CASE PRESENTATION
We report the case of a 51 year-old veteran from Guam, treated with ruxolitinib for polycythemia vera, who developed disseminated histoplasmosis and concurrent cryptococcal meningitis.


CONCLUSION
This case draws attention to the degree of immunosuppression that may be seen with this drug and the need for heightened vigilance for opportunistic infections in those treated with inhibitors of janus kinase/signal transducers and activators of transcription (JAK/STAT) such as ruxolitinib.
['Prakash|Katya|K|http://orcid.org/0000-0002-8653-4657', 'Richman|Douglas|D|']
D006141:Guam D006660:Histoplasmosis D006801:Humans D007108:Immune Tolerance D016867:Immunocompromised Host D000072742:Invasive Fungal Infections D008297:Male D016919:Meningitis, Cryptococcal D008875:Middle Aged D009570:Nitriles D011087:Polycythemia Vera D011720:Pyrazoles D011743:Pyrimidines D014728:Veterans
Histoplasmosis Ruxolitinib Immunosuppression Cryptococcus JAKinhibitor